Aurobindo Pharma Ltd. News and Updates

Name: Latest research reports of Aurobindo Pharma Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Keep track of all breaking news on Aurobindo Pharma Ltd. from all sources in a single place.

Load latest

Aurobindo Pharma Ltd.

20 Mar 2019

1094.40

-1.33%

Management Meet Update - Royal mix: Alert in Quality control and spurt in value chain of products

Buy: Aurobindo Pharma Ltd.

Prabhudas Lilladhar

resolution three times in past 18 months showcased commitment and cohesive organizational structure that professionally manages processes without dependence on key personnel. Noticing the operational risk among large peers in key markets, ARBP strategically envisaged alleviation of concentration risk and regulatory risk on key products/ plants/ markets. It's newly commissioned Unit-16, made to replicate products of Unit-12 for US market, additionally supplies injectable...

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1093.6

Aurobindo Pharma Ltd.

13 Mar 2019, 12:00AM

1094.40

-1.33%

Aurobindo Pharmaceuticals USFDA

Buy: Aurobindo Pharma Ltd.

Angel Broking

Aurobindo Pharmaceuticals (APL) has a big relief in form of Establishment Inspection report (EIR) for Unit-4 facility in which the USFDA has closed issued Form 483. The Form 483 is issued to a firms management at the conclusion of an inspection when an investigator(s) has observed any conditions that may constitute violations of the Food

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1132.4

Aurobindo Pharma Ltd.

06 Mar 2019

1094.40

-1.33%

Buys not enough, Aurobindo needs to show M&A; benefits

Economic Times

Unlike its peers, the company has steered clear from big-ticket acquisitions.

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

02 Mar 2019

1094.40

-1.33%

Aurobindo Pharma USA recalls 38 lots of Amlodipine Valsartan, Valsartan tablets

Business Line

Aurobindo Phrama USA has initiated a voluntary nationwide consumer level recall expansion of 38 lots of Amlodipine Valsartan tablets USP and Valsartan

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1132.4

Aurobindo Pharma Ltd.

27 Feb 2019

1094.40

-1.33%

Lacunae in Aurobindo Pharma's Medak facility in Andhra, says FDA report

Business Standard

Besides, the report said preparative apparel was not worn as necessary to protect drug products from contamination

Aurobindo Pharma Ltd. has lost -27.40% in the last 1 Year

Aurobindo Pharma Ltd.

14 Feb 2019

1094.40

-1.33%

Aurobindo Pharma Ltd. - Result Update - 14 February 2019

Results Update: Aurobindo Pharma Ltd.

Way2Wealth

Aurobindo Pharma's revenue grew 22% on a YoY basis to `5270 crs. in Q3. Growth was led by all business segments and markets. US and growth markets reported growth of 27% and 36% respectively on a YoY basis. Consolidated EBITDA increased to `1,086 Cr vs. `1,025 Cr in Q3 last year, an increase of...

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

12 Feb 2019, 12:31AM

1094.40

-1.33%

Aurobindo Pharma: US sales, European biz suggest drivers are in place

Business Standard

The acquired business is estimated to have annual sales of euro 130 million, according to analysts, and will add to Aurobindo's prospects in Europe

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1132.4

Aurobindo Pharma acquires Apotex's operations in 5 European countries

Business Line | 11 Feb 2019, 12:46PM

Aurobindo Pharma Ltd.

11 Feb 2019

1094.40

-1.33%

Aurobindo Pharma-3QFY19 Result Update

Aurobindo Pharma Ltd.

Reliance Securities

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

11 Feb 2019

1094.40

-1.33%

Q3FY19 Result Update - Q3 beats estimates; Poised to monetize Onco Inj

Buy: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

The Q3FY19 sales, adj. EBITDA and PAT beat our estimates by 9%, 3% and Change in Estimates | Target | Reco 8% respectively. While the injectable business was in line with guidance, its flat value erosion of US generics QoQ and efficient execution of new business...

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

09 Feb 2019

1094.40

-1.33%

Aurobindo Pharma (3QFY19): Riding on uptrend. Maintain NEUTRAL

Neutral: Aurobindo Pharma Ltd.

Target

HDFC Securities

Maintain NEUTRAL with a revised TP of Rs 800 (15x Dec-20E EPS). It is encouraging to see the US base businesses of many Indian pharma companies recovering sharply in 3QFY19, largely led by exit of big players. However, our concerns over Aurobindo (ARBP) remain related to the Sandoz acquisition, which will be completed by 1HFY20. We strongly believe that this acquisition will expand ARBPs exposure to commodity products and the portfolio will be highly prone to future competition.